Monopar Therapeutics (NASDAQ:MNPR) Stock: Insider Chandler Robinson Sells 29,056 Shares

Monopar Therapeutics Inc. (NASDAQ:MNPR) CEO Chandler Robinson sold 29,056 shares of the business’s stock in a transaction on Thursday, September 24th. The stock was sold at an average price of $88.00, for a total value of $2,556,928.00. Following the sale, the chief executive officer owned 99,267 shares of the company’s stock, valued at approximately $8,735,496. The trade was a 22.64% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Monopar Therapeutics Trading Down 1.8%

Shares of MNPR stock traded down $1.52 on Monday, reaching $83.72. The company had a trading volume of 268,172 shares, compared to its average volume of 134,390. Monopar Therapeutics Inc. has a 12 month low of $50.07 and a 12 month high of $124.82. The company has a 50-day moving average of $109.77 and a 200-day moving average of $82.32. The stock has a market cap of $561.76 million, a PE ratio of -38.58 and a beta of 1.49.

Monopar Therapeutics (NASDAQ:MNPR) last announced its earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.02. Sell-side analysts anticipate that Monopar Therapeutics Inc. will post -2.98 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Sei Investments Co. raised its stake in Monopar Therapeutics by 9.5% in the 1st quarter. Sei Investments Co. now owns 7,582 shares of the company’s stock valued at $415,000 after acquiring an additional 656 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Monopar Therapeutics during the 4th quarter valued at approximately $86,000. Your Advocates Ltd. LLP purchased a new stake in shares of Monopar Therapeutics during the 1st quarter valued at approximately $183,000. The Manufacturers Life Insurance Company bought a new position in Monopar Therapeutics in the 1st quarter worth approximately $250,000. Finally, Virtu Financial LLC bought a new position in Monopar Therapeutics in the 4th quarter worth approximately $654,000. 1.83% of the stock is owned by institutional investors.

Analysts Set New Price Targets

MNPR has been the subject of several research analyst reports. Piper Sandler set a $105.00 target price on shares of Monopar Therapeutics in a report on Tuesday, June 2nd. HC Wainwright boosted their price objective on Monopar Therapeutics from $105.00 to $125.00 and gave the stock a “buy” rating in a report on Wednesday, July 22nd. BTIG Research increased their target price on Monopar Therapeutics from $117.00 to $133.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Zacks Research cut shares of Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 13th. Finally, Barclays reaffirmed an “overweight” rating and issued a $145.00 price objective (up from $128.00) on shares of Monopar Therapeutics in a research note on Friday, September 11th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $121.36.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel treatments for cancer. The company’s programs are designed to address significant limitations associated with existing cancer therapies, including treatment resistance and dose-limiting toxicity.

Monopar’s lead clinical program is camsirubicin, an investigational next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The drug is designed to retain the anticancer activity of anthracyclines while reducing the risk of cumulative heart damage associated with conventional doxorubicin.